# Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

> **NCT03299686** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 118 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CJM112
- **OTHER:** Placebo to CJM112

## Key facts

- **NCT ID:** NCT03299686
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-06
- **Primary completion:** 2019-04-08
- **Final completion:** 2019-07-08
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03299686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03299686, "Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03299686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*